Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Bullboard (CSE:AGN)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by DIYPortfolio57on May 11, 2023 1:14pm

Algernon proceeding with Phase 1 of DMT trial. AGN

https://www.algernonpharmaceuticals.com/investors/company-information
140
Post by SkywalkerofLukeon May 10, 2023 3:27pm

CEO Interview

Here’s an interview with the AGN.c AGNPF CEO on their recent news that they received a notice of Allowance from the US Patent and Trademark Office for patent application for its lead chronic kidney ...more  
134
Post by SkywalkerofLukeon May 08, 2023 4:42pm

Recent News

AGN.c AGNPF is working to be a leader in the discovery of new therapeutic uses for drugs that are off patent and have a well-known safety history, but have never been marketed in the U.S. or Europe.  ...more  
159
Comment by C10H12N2on May 07, 2023 10:21pm

RE:RE:AGN now investigating CKD treatment

Dude, surfely, you're aware that it's merely a handful of penny stock bots doing the corps bidding here. You'll never get a legitimate debate regarding any questions deemed adversarial to ...more  
102
Discussion
Comment by Whalewatcher1on May 06, 2023 12:09pm

RE:AGN now investigating CKD treatment

StawkHawk1, so how do you think these guys will pay for CKD trial? They can only raise $1.2M on rights offering, don't have the funds to complete current trials/ideas, they spin out stroke program ...more  
112
Discussion
Post by StockHawk1on May 05, 2023 8:41pm

AGN now investigating CKD treatment

For everyone interested in biotech or pharma companies, Algernon Pharmaceuticals (AGN.c AGNPF) is a clinical-stage drug development and repurposing company that is currently investigating treatments ...more  
231
Discussion
Post by Whalewatcher1on May 05, 2023 5:31pm

Classic issue bad news after market closes on Friday . . .

so they could only raise $1.2M at $0.25 with major discount at time of offering (stock was ~$0.50 at offering w full warrant), so where do they go from here? They have been burning over $1.2M per ...more  
206
Comment by nodaytraderon May 03, 2023 11:29am

RE:RE:RE:RE:Results of rights offering? where is it?

Don't forget Chronic Cough. After the Phase 2 trial in Australia, some of the patients in the trial asked if they could continue to be treated with Ifenprodil. Presumably, these people had ...more  
90
Discussion
Comment by quicksilver545on May 01, 2023 11:17pm

RE:RE:RE:Results of rights offering? where is it?

Pharma companies are high risk, high reward, so that's what I mean by leveraged. So if phase 2-3 trials show efficacy, this will do well and recover. But the burn rate is high, so yes, they will ...more  
80
Discussion
Comment by Whalewatcher1on May 01, 2023 8:34pm

RE:RE:Results of rights offering? where is it?

thanks for the comment. The rights offering said offering expires 2:00 p.m. (Pacific time) on April 27, 2023 (the “Expiry Date”). Thus i would assume managment knows the number.  how mangement ...more  
87
Discussion
Comment by quicksilver545on May 01, 2023 8:10pm

RE:Results of rights offering? where is it?

Last press release said the rights offering will close on or before May 3, so I would look for a news release around then. It can take a few days to a week to collect all subscriptions and determine ...more  
66
Discussion
Post by Whalewatcher1on May 01, 2023 5:52pm

Results of rights offering? where is it?

Last Friday was deadline for shareholders to subscribe to rights offering. Shouldnt this have been disclosed by today? This would be considered material information as it directly related to the ...more  
119
Discussion
Post by SkywalkerofLukeon Apr 28, 2023 12:09pm

Videos on AGN

Recommend checking out some of the interviews/videos on AGN.c AGNPF. They are focused on discovering new therapeutic uses for drugs that are off patent (not patented) and have a well-known safety ...more  
91
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities